

**Supplemental fig. S1. Conjugation of PlGF-2123-144 peptide to CD40 activates dendritic cells without Fc crosslinking.**

Bone marrow-derived dendritic cells were incubated for 24 hr with either the isotype control rat IgG2a, PlGF-2123-144-CD40, CD40 and artificially crosslinked CD40 using crosslinking reagent (XL: anti-rat IgG Fc specific antibody) *in vitro*. Then, the expression of CD86 and CD80 were analyzed by flow cytometry. (mean ± SEM). Statistical analyses were done using ANOVA with Tukey’s test. \*\**p* < 0.01



**Supplemental fig. S2. Hepatocytes barely express CD40.**

The expression of *CD40* was measured in primary hepatocytes and total LN cells from naïve C57BL/6 mice by qPCR. Gene expression levels relative to *-Actin* are indicated (n = 3, mean ± SEM).



**Supplemental fig. S3. CD40 treatment did not alter frequency of NK cells.**

5 × 105 B16F10 cells were inoculated on day 0. 50 µg of PlGF-2123-144-CD40, CD40, or PBS was administered on day 4. CD40 was injected p.t.. Tumor and td-LN were taken on day 9, followed by flow cytometric analysis. Graphs depict the % of NK1.1+ cells of CD45+ cells A, in the tumor and B, in the td-LN (mean ± SEM). Statistical analyses were done using ANOVA with Tukey’s test.